A Chemically Defined Four‐Component Self‐Adjuvanting Tn Vaccine Activating Mincle, FcγR, and CD206 for Enhanced Antitumor Immunity
Advanced Science · 2026
DOI: 10.1002/advs.76235 ↗At a glance
Journal article in Advanced Science, 2026. Written by Wenbo Ming and 9 co-authors. Institution: Guangdong Provincial Key Laboratory of Translational Chinese Medicine, Joint International Research Laboratory of Translational Cancer Research of Ch…. Major MEDLINE topics: Cancer Vaccines, Receptors, IgG, Lectins, C-Type, Antigens, Tumor-Associated, Carbohydrate. Cited 1 times so far (Crossref); 53 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, National Key Research and Development Program of China, Department of Education of Guangdong Province.
Abstract (original language)
Tumor‐associated carbohydrate antigens (TACAs), such as the Tn antigen, are promising targets for cancer vaccines but are limited by their low immunogenicity and a lack of T‐cell responses. Traditional carrier‐protein conjugates often encounter issues such as epitope suppression and heterogeneous formulations. Herein, we present the design, synthesis, and immunological evaluation of a chemically defined, four‐component self‐adjuvanting glycoconjugate. This molecule combines multiple innate immune activation strategies into a single, unimolecular framework, incorporating (1) a synthetic Tn as the B‐cell epitope; (2) vizantin, a strong Mincle agonist, as an internal adjuvant; (3) rhamnose to attract endogenous antibodies for Fcγ receptor–mediated uptake; and (4) mannose to target dendritic cells through CD206. By ensuring precise co‐delivery and synergistic activation of Mincle, Fcγ receptor, and CD206 pathways, this construct induces strong IgG switching, Th1‑type cytokine responses, and significant tumor suppression in mice. This research offers a versatile chemical approach for next‑generation TACA vaccines, illustrating how activating multiple innate pathways can overcome the longstanding limitations of carbohydrate‐based immunotherapies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Guangdong Provincial Key Laboratory of Translational Chinese Medicine, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Med…
- Chinese Medicine Guangdong Laboratory, Hengqin, China.
- Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
- Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Second Military Medical University, Shanghai, China.
Funding
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Department of Education of Guangdong Province
- Guangdong Basic and Applied Basic Research Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
Cite
APA
Ming, W., Zhang, R., Li, X., Li, G., Niu, Y., Yang, D., Luo, X., Liao, J., Liu, Z., & Liao, G. (2026). A Chemically Defined Four‐Component Self‐Adjuvanting Tn Vaccine Activating Mincle, FcγR, and CD206 for Enhanced Antitumor Immunity. Advanced Science. https://doi.org/10.1002/advs.76235
Vancouver
Ming W, Zhang R, Li X, Li G, Niu Y, Yang D, et al. A Chemically Defined Four‐Component Self‐Adjuvanting Tn Vaccine Activating Mincle, FcγR, and CD206 for Enhanced Antitumor Immunity. Advanced Science. 2026. doi:10.1002/advs.76235
BibTeX
@article{Ming2026,
author = {Ming, Wenbo and Zhang, Renyu and Li, Xiaohui and Li, Guiqi and Niu, Yu and Yang, Deying and Luo, Xiang and Liao, Jun and Liu, Zhongqiu and Liao, Guochao},
title = {A Chemically Defined Four‐Component Self‐Adjuvanting Tn Vaccine Activating Mincle, FcγR, and CD206 for Enhanced Antitumor Immunity},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76235}
}
EUVIMED